Cytokinetics Inc
NASDAQ:CYTK

Watchlist Manager
Cytokinetics Inc Logo
Cytokinetics Inc
NASDAQ:CYTK
Watchlist
Price: 55.14 USD -1.47% Market Closed
Market Cap: 6.5B USD
Have any thoughts about
Cytokinetics Inc?
Write Note

EV/EBITDA
Enterprise Value to EBITDA

-12
Current
-13
Median
4.3
Industry
Higher than median
Lower than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
-12
=
Enterprise Value
6.1B USD
/
EBITDA
-511.7m USD
All Countries
Close
Market Cap EV/EBITDA
US
Cytokinetics Inc
NASDAQ:CYTK
6.5B USD -12
FR
Pharnext SCA
OTC:PNEXF
6T USD -216 796.7
US
Abbvie Inc
NYSE:ABBV
300.2B USD 14.8
US
Amgen Inc
NASDAQ:AMGN
158.7B USD 17.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
126.8B USD 26.8
US
Gilead Sciences Inc
NASDAQ:GILD
115B USD 10.1
US
Epizyme Inc
F:EPE
94.1B EUR -521.2
AU
CSL Ltd
ASX:CSL
137.3B AUD 20.8
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
88.3B USD 17.4
US
Seagen Inc
F:SGT
39.3B EUR -59.5
NL
argenx SE
XBRU:ARGX
34.1B EUR -104.5
EBITDA Growth
US
Cytokinetics Inc
NASDAQ:CYTK
Average EV/EBITDA: 17.9
Negative Multiple: -12
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -216 796.7 N/A
US
Abbvie Inc
NYSE:ABBV
14.8
28%
US
Amgen Inc
NASDAQ:AMGN
17.5
63%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
26.8
38%
US
Gilead Sciences Inc
NASDAQ:GILD
10.1
12%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -521.2 N/A
AU
CSL Ltd
ASX:CSL
20.8
42%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.4
46%
US
S
Seagen Inc
F:SGT
Negative Multiple: -59.5 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -104.5 N/A

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
-11.3
2-Years Forward
EV/EBITDA
-11.3
3-Years Forward
EV/EBITDA
-17.2

See Also

Discover More